[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100588015":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":24,"locations":30,"responsibleParty":76,"collaborators":11,"id":78,"slug":11,"hasResults":79,"nctId":80,"briefTitle":81,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":79,"sex":84,"minAge":85,"maxAge":11,"enrollmentInfo":86,"targetDuration":11,"studyType":89,"phases":90,"briefSummary":92,"conditions":93,"keywords":97,"overallStatus":33,"whyStopped":11,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":111},{"fullName":5,"class":6},"Murdoch Childrens Research Institute","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Participants who have completed Jack Jumper Ant Venom Immmunotherapy treatment","EXPERIMENTAL",null,[13],"Other: Jack Jumper Ant Venom Immunotherapy",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":11},"Jack Jumper Ant Venom Immunotherapy","Jack Jumper Ant Venom Immunotherapy involves injections, under the skin, of gradually increasing doses of insect venom. The treatment is usually between 3-\\\u003C6 years duration. Participants will have completed this treatment at least 18 months prior to their enrolment in this trial.",[9],[20],{"name":21,"affiliation":22,"role":23},"Adriana Le, MBBS FRACP","Royal Hobart Hospital","PRINCIPAL_INVESTIGATOR",[25],{"name":26,"role":27,"phone":28,"phoneExt":11,"email":29},"National Allergy Centre of Excellence","CONTACT","61 3 99366752","nace@mcri.edu.au",[31,49,62],{"facility":32,"status":33,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Royal Adelaide Hospital","RECRUITING","Adelaide","South Australia","5000","Australia","AU",{"type":40,"coordinates":41},"Point",[42,43],138.59863,-34.92866,{"lat":43,"lon":42},[46,47],{"name":26,"role":27,"phone":28,"phoneExt":11,"email":29},{"name":48,"role":23,"phone":11,"phoneExt":11,"email":11},"Carlo Yuson, MD FRACP",{"facility":22,"status":33,"city":50,"state":51,"zip":52,"country":37,"countryCode":38,"cosmosGeoPoint":53,"geoPoint":57,"contacts":58},"Hobart","Tasmania","7000",{"type":40,"coordinates":54},[55,56],147.32941,-42.87936,{"lat":56,"lon":55},[59,60],{"name":26,"role":27,"phone":28,"phoneExt":11,"email":29},{"name":61,"role":23,"phone":11,"phoneExt":11,"email":11},"Troy Wanandy, PhD",{"facility":63,"status":33,"city":64,"state":65,"zip":66,"country":37,"countryCode":38,"cosmosGeoPoint":67,"geoPoint":71,"contacts":72},"Monash Medical Centre","Clayton","Victoria","3168",{"type":40,"coordinates":68},[69,70],145.11667,-37.91667,{"lat":70,"lon":69},[73,74],{"name":26,"role":27,"phone":28,"phoneExt":11,"email":29},{"name":75,"role":23,"phone":11,"phoneExt":11,"email":11},"Kymble Spriggs, MBBS MPH FRACP FRCP FAAAAI",{"type":77,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100588015",false,"NCT06935890","Jack Jumper Ant Venom Immunotherapy Long-term Effectiveness Investigation","JAVELIN","Eligibility criteria\n\n\\- Any adult (≥ 18 years) who has completed a JJA VIT program at one of the three participating sites.\n\nInclusion Criteria:\n\n1. Completed a continuous program of JJA VIT of between 3 and \\\u003C 6 years duration.\n2. Have ceased JJA VIT for ≥ 18 months but \\\u003C 5 years.\n3. Have the ability to provide informed consent.\n\nExclusion Criteria:\n\n1. Any person \\\u003C 18 years.\n2. Any adult (≥ 18 years) who has not completed a continuous JJA VIT program of duration between 3 and \\\u003C 6 years.\n3. Any adult (≥ 18 years) who has completed a continuous JJA VIT program of duration between 3 and \\\u003C 6 years but ceased JJA VIT \\\u003C 18 months or \\> 5 years ago.\n4. Any person who has a medical condition, that in the opinion of the investigator, may place them at increased risk if they were to have a sting challenge.\n5. Unable to understand study requirements and provide informed consent.","ALL","18 Years",{"count":87,"type":88},100,"ESTIMATED","INTERVENTIONAL",[91],"PHASE4","Jack Jumper ant (JJA) venom allergy is a uniquely Australian medical condition. It is the leading cause of venom allergy and affects up to three per cent of the population. 70 percent of people with JJA allergy will have another reaction on a repeat sting and this sensitivity appears to persist for many years.\n\nVenom immunotherapy (VIT) has been shown to be a safe and effective treatment in the prevention of severe systemic allergic reactions (anaphylaxis) to future stings. It is currently offered to patients as standard care in Tasmania, South Australia and Victoria. However, whilst JJA VIT has been used for many years, there is a lack of evidence on the long-term benefit of the treatment and how it impacts patient quality of life.\n\nThis trial will offer patients who have completed a JJA VIT program (between 3 and \\\u003C 6-years duration) and have been off-treatment for at least 18-months and \\\u003C 5 years, to have a supervised JJA sting challenge and blood test to assess their JJA venom tolerance level. It will also ask them to complete a set of questionnaires at different timepoints to obtain a history of their exposure and reactions to JJA stings outside of the hospital setting (field stings), and to measure the impact of the completed VIT and knowledge of their sting challenge outcome on their quality of life and their behaviours around auto-injectors.\n\nThese measures will be used to explore the long-term effectiveness of JJA VIT and the impact of a sting challenge post VIT on a patient's quality of life.",[94,95,96],"Allergy","Immunotherapy","Venom Allergy",[98,99,100,101],"Jack Jumper Ant","Venom Immunotherapy","Sting challenge","VIT","2026-03-29",{"date":104,"type":105},"2026-03-31","ACTUAL",{"date":107,"type":105},"2025-11-25",{"date":109,"type":88},"2029-10",{"name":5,"class":6},3]